Player FM - Internet Radio Done Right
Checked 13d ago
Lagt til twenty-one uker siden
Inhalt bereitgestellt von Joe Brunetto. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Joe Brunetto oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!
Gehen Sie mit der App Player FM offline!
WTR Biotech Spotlight
Alle als (un)gespielt markieren ...
Manage series 3645695
Inhalt bereitgestellt von Joe Brunetto. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Joe Brunetto oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
WTR Biotech Spotlight is a biweekly conversation with biotech executives, medical experts, and investors on recent clinical data or industry-driving events in biotech.
13 Episoden
Alle als (un)gespielt markieren ...
Manage series 3645695
Inhalt bereitgestellt von Joe Brunetto. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Joe Brunetto oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
WTR Biotech Spotlight is a biweekly conversation with biotech executives, medical experts, and investors on recent clinical data or industry-driving events in biotech.
13 Episoden
Alle episoder
×
1 A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape 24:20
In this episode of the WTR Biotech Spotlight , Water Tower Research’s Tim Gerdeman is joined by Nick Kadysh , Founding CEO and President of Toronto-headquartered Life Sciences company, PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF) ,and WTR Senior Analyst Robert Sassoon for an insightful discussion on arguably the two main topics that are currently concentrating the minds of biotech industry folk: The implications of the Trump Administration's FDA reforms and AI's role in reshaping the industry. With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kadysh founded PharmAla in 2020 to focused on the manufacturing and development of MDMA and MDMA-related molecules. Kadysh is also a prominent spokesman for the deployment of AI in drug discovery,…
Trevi Therapeutics CEO Jennifer Good joins us on this week’s WTR Biotech Spotlight to talk about the recent and impressive clinical data for Haduvio in IPF-associated chronic cough and refractory chronic cough. We discuss Haduvio’s unique mechanism and unscheduled status, supported by a human abuse study. Listen to learn more about Trevi Therapeutics and how Haduvio could change the chronic cough treatment landscape.…

1 How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski 14:57
In this episode of the WTR Biotech Spotlight , Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski , CEO of Psilera , and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies. Dr. Chris Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape. Tune in to learn more about Psilera’s vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.…

1 Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions 29:42
On this week’s WTR Biotech Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.…

1 Zomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare Market 17:48
CEO of Zomedica (OTCQB: ZOMDF) Larry Heaton joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Small-Cap Spotlight episode. Since 2021 Zomedica has expanded its suite of innovative offerings from one product to six. All are proprietary, highly differentiated either diagnostic or therapeutic devices, to help veterinarians not only improve the quality of care for pets, but also importantly to help improve the efficiency of how vets themselves operate to maximize the profitability of their practices. Heaton provides a concise overview of Zomedica’s products, explains how they differentiate themselves from what exists in the market today and the company’s growth opportunities.…

1 Enlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis Data 27:34
Enlivex Therapeutics CEO Oren Hershkovitz, PhD joins us on this week’s WTR Biotech Spotlight to talk about how the company’s cell therapy, Allocetra, reprograms macrophages to treat inflammatory diseases. We dive into the recent Phase 1 data in knee osteoarthritis and what to expect from the randomized Phase 2 readout later this year, as well as the market opportunity. Listen to learn more about Enlivex Therapeutics and its off-the-shelf cell therapy platform.…
Tim Gerdeman and Do Kim discuss President Trump’s executive order on lowering drug prices through Most-Favored-Nation reference pricing. They talk about the goal of the executive order and whether the government has the authority for price-setting in the pharmaceutical industry.
Tim Gerdeman and Do Kim discuss the current state of biotech, what brought us here, and how the rest of year may look for the group. They also review recent market-shaping events in the obesity space and progress of the Keytruda-busting PD-1/VEGF bispecifics.
On this week's episode of WTR Biotech Spotlight, Tim Gerdeman and Robert Sassoon sit down for a quick flashcast to review Robert's last three reports; Neuroscience, Alzheimer’s and Biogen IOC.

1 Annovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next Steps 18:23
Founding CEO and President of Annovis Bio (NYSE: ANVS) Dr Maria Maccecchini joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Biotech Spotlight episode. Annovis is a late clinical-stage drug platform company developing novel disease-modifying therapies for neurodegenerative diseases, to include targeting Alzheimer's and Parkinson's, as well as other related diseases. Dr Maccecchini discusses the company's lead drug candidate Buntanetap and its promise as a treatment that can go beyond simply slowing the rate of cognitive decline in Alzheimer's and Parkinson's patients.…

1 Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs 34:32
CEO Mitch Steiner joins us on this week’s WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm…

1 OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps 25:42
CEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.…
We are launching a WTR Spotlight podcast focused on biotech companies and industry. Listen to Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Do Kim, Senior Research Analyst, discuss what to expect and who will be joining us in future episodes.
Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.